News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – July

AR-13324-CS208 Japan Phase 2 Study Topline Results

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Announces $125 Million Convertible Notes
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it
View HTML
Toggle Summary Aerie Announces Closing of $125 Million Convertible Notes Financing
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it
View HTML
Toggle Summary Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI)
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif. --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with
View HTML
Toggle Summary Aerie Pharmaceuticals and GrayBug Announce Research Collaboration
Focused on Novel Delivery Technologies for Aerie Product Candidates IRVINE, Calif. & BALTIMORE --(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
TOP